Nkarta NKTX 深 沪
已收盘 07-02 16:00:00 美东时间
3.22
+0.370
+12.98%
华盛通- 最 高3.275
- 今 开2.87
- 成交量 150.19万股
- 最 低 2.82
- 昨 收 2.85
- 总市值 2.30亿
- 52周最高 3.65
- 市盈率 静 --
- 换手率 2.10%
- 52周最低 1.70
- 委 比 30.57%
- 总股本 7154.54万
- 历史最高 79.16
- 量 比 2.14
- 振 幅 15.96%
- 历史最低 1.28
- 每 手 1
- 风险率 0.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nkarta joins H.C. Wainwright Cell Therapy Virtual Conference fireside chat
Nkarta joins H.C. Wainwright Cell Therapy Virtual Conference fireside chat Nkarta will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30. President Nadir Mahmood is scheduled for a 2 p.m. ET fireside chat covering updates on its investigational CAR-NK program i
06-26 20:45
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Nkarta, Inc. will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. Nkarta President Nadir Mahmood will discuss updates on the company’s investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases during a fireside chat at 2 p.m. ET. The discussion will be webcast live and available for replay on Nkarta’s investor website for 90 days. Nkarta is a clinical-stage biotech company developi...
06-26 12:45
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Needham Reiterates Buy on Nkarta, Maintains $11 Price Target
Needham analyst Gil Blum reiterates Nkarta (NASDAQ:NKTX) with a Buy and maintains $11 price target.
05-13 18:45
Nkarta Q1 EPS $(0.37), Inline
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.37) per share which met the analyst consensus estimate. This is a 13.95 percent increase over losses of $(0.43) per share from the same period last year.
05-13 04:33
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
Nkarta reported Q1 2026 financial results with a cash balance of $266.7 million, supporting operations into 2029. Enrollment continues in Ntrust-1 and Ntrust-2 trials at 4 billion cell dose levels. FDA agreement allows outpatient dosing and expansion to community settings. Initial clinical data expected in 2026. R&D expenses were $25.0 million, G&A expenses $5.9 million, resulting in a net loss of $27.8 million.
05-12 20:01
Nkarta rises on FDA agreement for amended trial protocol
Nkarta (NKTX) added ~13% on Thursday after the cell therapy developer said that the company reached an agreement with the U.S. FDA to change the protocol of a clinical program that allows outpatient d...
04-17 01:38
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
